AstraZeneca ADR


SKU: AZN Category:


AstraZeneca PLC: Can The Amolyt Pharma Acquisition Be A Game Changer? 


AstraZeneca’s Fourth quarter and full-year ’23 earnings reflects strong performance. Notably, the company achieved their decade-long target of $45 billion sales, demonstrating its consistent focus on long-term growth. The company’s diverse commodity areas, ranging from oncology to rare diseases, all demonstrated strong growth in 2023, with the company’s profitability expected to increase because of this.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!